| ￥3500 | |
| Z06332-100 | |
|
|
|
|
|
|
|
|
|
| Species | Mouse | ||||||
| Protein Construction |
|
||||||
| Purity | > 95% as determined by Bis-Tris PAGE | ||||||
| Endotoxin Level | Less than 1EU per μg by the LAL method. | ||||||
| Biological Activity | Measured by its binding ability in a functional ELISA. Immobilized Mouse Nectin2, His Tag at 5μg/ml (100μl/well) on the plate can bind PVRIG hFc Chimera, Avi, Mouse. Test result was comparable to standard batch. | ||||||
| Expression System | HEK293 | ||||||
| Theoretical Molecular Weight | 42.70 kDa | ||||||
| Apparent Molecular Weight | Due to glycosylation, the protein migrates to 53-63 kDa based on Bis-Tris PAGE result. | ||||||
| Formulation | Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). | ||||||
| Reconstitution | Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. | ||||||
| Storage & Stability | Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles. |
| Target Background | Murine PVRIG interacted weakly with poliovirus receptor (PVR) but bound poliovirus receptor-like 2 (PVRL2) strongly, making the latter its principal ligand.PVRIG is an inducible checkpoint receptor and that targeting PVRIG-PVRL2 interactions results in increased CD8+ T-cell function and reduced tumor growth. |
| Synonyms | C7orf15; CD112R; MGC104322; MGC138297; MGC2463; PVRIG; ALS2CR18; ALS2CR9; LPD; PREL-2; PREL2; RalGDS/AF-6; RMO1 |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
